Skip to main content
Top
Published in: Diabetologia 1/2006

01-01-2006 | Article

Glucagon secretion in relation to insulin sensitivity in healthy subjects

Author: B. Ahrén

Published in: Diabetologia | Issue 1/2006

Login to get access

Abstract

Aims/hypothesis

The study evaluated whether glucagon secretion is regulated by changes in insulin sensitivity under normal conditions.

Materials and methods

A total of 155 healthy women with NGT (aged 53–70 years) underwent a glucose-dependent arginine-stimulation test for evaluation of glucagon secretion. Arginine (5 g) was injected i.v. under fasting conditions (plasma glucose 4.8±0.1 mmol/l) and after raising blood glucose concentrations to 14.8±0.1 and 29.8±0.2 mmol/l. The acute glucagon response (AGR) to arginine during the three glucose levels (AGR1, AGR2, AGR3) was estimated, as was the suppression of baseline glucagon by the increased glucose. All women also underwent a 2-h euglycaemic–hyperinsulinaemic clamp study for estimation of insulin sensitivity.

Results

Insulin sensitivity was normally distributed, with a mean of 73.2±29.3 (SD) nmol glucose kg−1 min−1/pmol insulin l−1. When relating the variables obtained from the arginine test to insulin sensitivity, insulin resistance was associated with increased AGR and with increased suppression of glucagon levels by glucose. For example, the regression between insulin sensitivity and AGR2 was r=−0.38 (p<0.001) and between insulin sensitivity and suppression of glucagon levels by 14.8 mmol/l glucose r=0.36 (p<0.001). Insulin sensitivity also correlated negatively with insulin secretion; multivariate analysis revealed that changes in insulin sensitivity and insulin secretion were independently related to changes in glucagon secretion.

Conclusions/interpretation

The body adapts to insulin resistance by increasing the glucagon response to arginine and by increasing the suppression of glucagon levels by glucose. Hence, not only the islet beta cells but also the alpha cells seem to undergo compensatory changes during the development of insulin resistance.
Literature
1.
go back to reference Reaven GM, Hollenbeck CB, Chen YDI (1989) Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia 32:52–55PubMedCrossRef Reaven GM, Hollenbeck CB, Chen YDI (1989) Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia 32:52–55PubMedCrossRef
2.
go back to reference De Fronzo RA, Bonadonna RC, Ferrannini E (1992) Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15:318–368CrossRef De Fronzo RA, Bonadonna RC, Ferrannini E (1992) Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15:318–368CrossRef
3.
go back to reference Ahrén B, Pacini G (2004) Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol 150:97–104PubMedCrossRef Ahrén B, Pacini G (2004) Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol 150:97–104PubMedCrossRef
4.
go back to reference Muller WA, Faloona GR, Aguilar-Parada E, Unger RH (1970) Abnormal α-cell function in diabetes. N Engl J Med 283:109–115PubMedCrossRef Muller WA, Faloona GR, Aguilar-Parada E, Unger RH (1970) Abnormal α-cell function in diabetes. N Engl J Med 283:109–115PubMedCrossRef
5.
go back to reference Reaven GM, Chen YD, Golay A et al. (1987) Documentation of hyperglucagonaemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106–110PubMedCrossRef Reaven GM, Chen YD, Golay A et al. (1987) Documentation of hyperglucagonaemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106–110PubMedCrossRef
6.
go back to reference Butler PC, Rizza RA (1991) Contribution to postprandial hyperglycaemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 40:73–81PubMedCrossRef Butler PC, Rizza RA (1991) Contribution to postprandial hyperglycaemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 40:73–81PubMedCrossRef
7.
go back to reference Unger RH, Orci L (1981) Glucagon and the A cell: physiology and pathophysiology, part 1. N Engl J Med 304:1518–1524PubMedCrossRef Unger RH, Orci L (1981) Glucagon and the A cell: physiology and pathophysiology, part 1. N Engl J Med 304:1518–1524PubMedCrossRef
8.
go back to reference Unger RH, Orci L (1981) Glucagon and the A cell: physiology and pathophysiology, part 2. N Engl J Med 304:1575–1580PubMedCrossRef Unger RH, Orci L (1981) Glucagon and the A cell: physiology and pathophysiology, part 2. N Engl J Med 304:1575–1580PubMedCrossRef
9.
10.
go back to reference Ahrén B, Larsson H (2000) Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care 23:650–657PubMedCrossRef Ahrén B, Larsson H (2000) Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care 23:650–657PubMedCrossRef
11.
go back to reference Ahrén B, Larsson H (2001) Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 44:1998–2003PubMedCrossRef Ahrén B, Larsson H (2001) Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 44:1998–2003PubMedCrossRef
12.
go back to reference Shah P, Vella A, Basu A et al. (2000) Lack of suppression of glucagon contributes to postprandial hyperglycaemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053–4059PubMedCrossRef Shah P, Vella A, Basu A et al. (2000) Lack of suppression of glucagon contributes to postprandial hyperglycaemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053–4059PubMedCrossRef
13.
go back to reference Shah P, Basu A, Basu R, Rizza R (1999) Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 277:E283–E290PubMed Shah P, Basu A, Basu R, Rizza R (1999) Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 277:E283–E290PubMed
14.
go back to reference Larsson H, Ahrén B, Lindgärde F, Berglund G (1995) Fasting blood glucose in determining the prevalence of diabetes in a large, homogeneous population of Caucasian middle-aged women. J Intern Med 237:537–541PubMed Larsson H, Ahrén B, Lindgärde F, Berglund G (1995) Fasting blood glucose in determining the prevalence of diabetes in a large, homogeneous population of Caucasian middle-aged women. J Intern Med 237:537–541PubMed
15.
go back to reference Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr (1984) Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 74:1318–1328PubMed Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr (1984) Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 74:1318–1328PubMed
16.
go back to reference Larsson H, Ahrén B (1998) Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine. Diabetologia 41:772–777PubMedCrossRef Larsson H, Ahrén B (1998) Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine. Diabetologia 41:772–777PubMedCrossRef
17.
go back to reference DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223PubMed DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223PubMed
18.
go back to reference Bergman RN, Phillips LS, Cobelli C (1981) Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456–1467PubMed Bergman RN, Phillips LS, Cobelli C (1981) Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456–1467PubMed
19.
go back to reference Kahn SE, Prigeon RL, McCulloch DK et al. (1993) Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663–1672PubMedCrossRef Kahn SE, Prigeon RL, McCulloch DK et al. (1993) Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663–1672PubMedCrossRef
20.
go back to reference Van Haeften TW, Pimenta W, Mitrakou A et al. (2000) Relative contributions of β-cell function and tissue insulin sensitivity to fasting and postload glycaemia. Metabolism 49:1318–1325PubMedCrossRef Van Haeften TW, Pimenta W, Mitrakou A et al. (2000) Relative contributions of β-cell function and tissue insulin sensitivity to fasting and postload glycaemia. Metabolism 49:1318–1325PubMedCrossRef
21.
go back to reference Ahrén B, Larsson H (2002) Quantification of insulin secretion in relation to insulin sensitivity in nondiabetic postmenopausal women. Diabetes 52 [Suppl 1]:202–211CrossRef Ahrén B, Larsson H (2002) Quantification of insulin secretion in relation to insulin sensitivity in nondiabetic postmenopausal women. Diabetes 52 [Suppl 1]:202–211CrossRef
22.
go back to reference Larsson H, Ahrén B (2000) Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women. Diabetologia 43:194–202PubMedCrossRef Larsson H, Ahrén B (2000) Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women. Diabetologia 43:194–202PubMedCrossRef
23.
go back to reference Ahrén B, Pacini G (2003) Signals adapting the beta cells to changes in insulin sensitivity. Int Congr Ser 1253:105–113CrossRef Ahrén B, Pacini G (2003) Signals adapting the beta cells to changes in insulin sensitivity. Int Congr Ser 1253:105–113CrossRef
24.
go back to reference Maruyama H, Hisatomi A, Orci L et al. (1984) Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest 74:2296–2299PubMedCrossRef Maruyama H, Hisatomi A, Orci L et al. (1984) Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest 74:2296–2299PubMedCrossRef
26.
Metadata
Title
Glucagon secretion in relation to insulin sensitivity in healthy subjects
Author
B. Ahrén
Publication date
01-01-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0056-8

Other articles of this Issue 1/2006

Diabetologia 1/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine